Vantage Hemp has submitted a Drug Master File (“DMF”) to the U.S. Food & Drug Administration (“FDA”) covering its hemp-derived cannabidiol (“CBD”) distillate. According to the announcement, the submission further reinforces Vantage as a transparent, reliable and compliant partner, committed to working with pharmaceutical companies to formulate its CBD active pharmaceutical ingredient (“API”). The filing, which also strengthens Vantage’s position as an industry leader, represents the company’s commitment to support its clients through all phases of drug development. The company also noted that it anticipates filing future DMF submissions as it works to deliver superior API quality. “Our distillate DMF filing is a testament to Vantage’s dedication to manufacturing the highest-quality CBD API,” said Vantage’s Chief Operating Officer Deepank Utkhede in the press release. “Vantage exemplifies the breadth of knowledge, depth of collaboration, and attention to detail expected and required of an API producer.”
To view the full press release, visit https://ibn.fm/umlVN
About Vantage Hemp Co.
With large-scale extraction facilities, Colorado-based Vantage Hemp delivers pharmaceutical-grade GMP-compliant CBD extracts, including full-spectrum oil, distillate, and isolate, that companies can trust. Vantage’s contract manufacturing services offer a broad range of benefits as the company operates with integrity and abides by stringent pharmaceutical-production standards to provide quality products to its partners. For more information about the company, please visit www.VantageHemp.com
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.